APO Research
Talk to an analyst

APO RESEARCH · REPORT

Malignant Mesothelioma Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Malignant Mesothelioma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025192 pages

Choose your research edition.

Industry ResearchMalignant Mesothelioma Drugs Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal Malignant Mesothelioma Drugs Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Malignant Mesothelioma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Malignant Mesothelioma Drugs Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Malignant Mesothelioma Drugs Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Malignant Mesothelioma Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Malignant Mesothelioma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Malignant Mesothelioma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Malignant Mesothelioma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Malignant Mesothelioma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Malignant Mesothelioma Drugs include Teva Pharmaceuticals, Sun Pharmaceuticals, Sanofi, Novartis, Merck, Mylan, Roche, Eli Lilly and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Malignant Mesothelioma Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Malignant Mesothelioma Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Malignant Mesothelioma Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Malignant Mesothelioma Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Malignant Mesothelioma Drugs Segment by Company

Teva Pharmaceuticals

Sun Pharmaceuticals

Sanofi

Novartis

Merck

Mylan

Roche

Eli Lilly

Pfizer

Fresenius Kabi

AstraZeneca

Polaris Pharmaceuticals

Ono Pharmaceutical

Nichi-Iko Pharmaceutical

MolMed

Kyowa Hakko Kirin

Corden Pharma

Concordia International

Bristol-Myers Squibb

Boehringer Ingelheim GmbH

Malignant Mesothelioma Drugs Segment by Type

Vinorelbine

Cisplatin

Pemetrexed

Carboplatin

Gemcitabine

Others

Malignant Mesothelioma Drugs Segment by Application

Retail Pharmacies

Hospital Pharmacies

Oncology Centers

Others

Malignant Mesothelioma Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Malignant Mesothelioma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Malignant Mesothelioma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Malignant Mesothelioma Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Malignant Mesothelioma Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Malignant Mesothelioma Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Malignant Mesothelioma Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Malignant Mesothelioma Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Malignant Mesothelioma Drugs Industry Trends Table 2. Malignant Mesothelioma Drugs Industry Drivers Table 3. Malignant Mesothelioma Drugs Industry Opportunities and Challenges Table 4. Malignant Mesothelioma Drugs Industry Restraints Table 5. Global Malignant Mesothelioma Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Malignant Mesothelioma Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Malignant Mesothelioma Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Malignant Mesothelioma Drugs Sales Market Share by Manufacturers Table 9. Global Malignant Mesothelioma Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Malignant Mesothelioma Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Malignant Mesothelioma Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Malignant Mesothelioma Drugs Manufacturers, Product Type & Application Table 13. Global Malignant Mesothelioma Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Malignant Mesothelioma Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Vinorelbine Table 17. Major Manufacturers of Cisplatin Table 18. Major Manufacturers of Pemetrexed Table 19. Major Manufacturers of Carboplatin Table 20. Major Manufacturers of Gemcitabine Table 21. Major Manufacturers of Others Table 22. Global Malignant Mesothelioma Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (K Units) Table 24. Global Malignant Mesothelioma Drugs Sales by Type (2027-2032) & (K Units) Table 25. Global Malignant Mesothelioma Drugs Sales Market Share by Type (2021-2026) Table 26. Global Malignant Mesothelioma Drugs Sales Market Share by Type (2027-2032) Table 27. Global Malignant Mesothelioma Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Malignant Mesothelioma Drugs Revenue by Type (2021-2026) & (K Units) Table 29. Global Malignant Mesothelioma Drugs Revenue by Type (2027-2032) & (K Units) Table 30. Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2021-2026) Table 31. Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Retail Pharmacies Table 33. Major Manufacturers of Hospital Pharmacies Table 34. Major Manufacturers of Oncology Centers Table 35. Major Manufacturers of Others Table 36. Global Malignant Mesothelioma Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (K Units) Table 38. Global Malignant Mesothelioma Drugs Sales by Application (2027-2032) & (K Units) Table 39. Global Malignant Mesothelioma Drugs Sales Market Share by Application (2021-2026) Table 40. Global Malignant Mesothelioma Drugs Sales Market Share by Application (2027-2032) Table 41. Global Malignant Mesothelioma Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Malignant Mesothelioma Drugs Revenue by Application (2021-2026) & (K Units) Table 43. Global Malignant Mesothelioma Drugs Revenue by Application (2027-2032) & (K Units) Table 44. Global Malignant Mesothelioma Drugs Revenue Market Share by Application (2021-2026) Table 45. Global Malignant Mesothelioma Drugs Revenue Market Share by Application (2027-2032) Table 46. Global Malignant Mesothelioma Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Malignant Mesothelioma Drugs Sales by Region (2021-2026) & (K Units) Table 48. Global Malignant Mesothelioma Drugs Sales Market Share by Region (2021-2026) Table 49. Global Malignant Mesothelioma Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global Malignant Mesothelioma Drugs Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Malignant Mesothelioma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America Malignant Mesothelioma Drugs Sales by Country (2021-2026) & (K Units) Table 53. North America Malignant Mesothelioma Drugs Sales by Country (2027-2032) & (K Units) Table 54. Europe Malignant Mesothelioma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe Malignant Mesothelioma Drugs Sales by Country (2021-2026) & (K Units) Table 56. Europe Malignant Mesothelioma Drugs Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific Malignant Mesothelioma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific Malignant Mesothelioma Drugs Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific Malignant Mesothelioma Drugs Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa Malignant Mesothelioma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa Malignant Mesothelioma Drugs Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa Malignant Mesothelioma Drugs Sales by Country (2027-2032) & (K Units) Table 63. Global Malignant Mesothelioma Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Malignant Mesothelioma Drugs Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Malignant Mesothelioma Drugs Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Malignant Mesothelioma Drugs Revenue Market Share by Region (2021-2026) Table 67. Global Malignant Mesothelioma Drugs Revenue Market Share by Region (2027-2032) Table 68. Teva Pharmaceuticals Company Information Table 69. Teva Pharmaceuticals Business Overview Table 70. Teva Pharmaceuticals Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Teva Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio Table 72. Teva Pharmaceuticals Recent Development Table 73. Sun Pharmaceuticals Company Information Table 74. Sun Pharmaceuticals Business Overview Table 75. Sun Pharmaceuticals Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Sun Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio Table 77. Sun Pharmaceuticals Recent Development Table 78. Sanofi Company Information Table 79. Sanofi Business Overview Table 80. Sanofi Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Sanofi Malignant Mesothelioma Drugs Product Portfolio Table 82. Sanofi Recent Development Table 83. Novartis Company Information Table 84. Novartis Business Overview Table 85. Novartis Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Novartis Malignant Mesothelioma Drugs Product Portfolio Table 87. Novartis Recent Development Table 88. Merck Company Information Table 89. Merck Business Overview Table 90. Merck Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Merck Malignant Mesothelioma Drugs Product Portfolio Table 92. Merck Recent Development Table 93. Mylan Company Information Table 94. Mylan Business Overview Table 95. Mylan Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Mylan Malignant Mesothelioma Drugs Product Portfolio Table 97. Mylan Recent Development Table 98. Roche Company Information Table 99. Roche Business Overview Table 100. Roche Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Roche Malignant Mesothelioma Drugs Product Portfolio Table 102. Roche Recent Development Table 103. Eli Lilly Company Information Table 104. Eli Lilly Business Overview Table 105. Eli Lilly Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Eli Lilly Malignant Mesothelioma Drugs Product Portfolio Table 107. Eli Lilly Recent Development Table 108. Pfizer Company Information Table 109. Pfizer Business Overview Table 110. Pfizer Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Pfizer Malignant Mesothelioma Drugs Product Portfolio Table 112. Pfizer Recent Development Table 113. Fresenius Kabi Company Information Table 114. Fresenius Kabi Business Overview Table 115. Fresenius Kabi Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Fresenius Kabi Malignant Mesothelioma Drugs Product Portfolio Table 117. Fresenius Kabi Recent Development Table 118. AstraZeneca Company Information Table 119. AstraZeneca Business Overview Table 120. AstraZeneca Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. AstraZeneca Malignant Mesothelioma Drugs Product Portfolio Table 122. AstraZeneca Recent Development Table 123. Polaris Pharmaceuticals Company Information Table 124. Polaris Pharmaceuticals Business Overview Table 125. Polaris Pharmaceuticals Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Polaris Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio Table 127. Polaris Pharmaceuticals Recent Development Table 128. Ono Pharmaceutical Company Information Table 129. Ono Pharmaceutical Business Overview Table 130. Ono Pharmaceutical Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Ono Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio Table 132. Ono Pharmaceutical Recent Development Table 133. Nichi-Iko Pharmaceutical Company Information Table 134. Nichi-Iko Pharmaceutical Business Overview Table 135. Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio Table 137. Nichi-Iko Pharmaceutical Recent Development Table 138. MolMed Company Information Table 139. MolMed Business Overview Table 140. MolMed Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. MolMed Malignant Mesothelioma Drugs Product Portfolio Table 142. MolMed Recent Development Table 143. Kyowa Hakko Kirin Company Information Table 144. Kyowa Hakko Kirin Business Overview Table 145. Kyowa Hakko Kirin Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Kyowa Hakko Kirin Malignant Mesothelioma Drugs Product Portfolio Table 147. Kyowa Hakko Kirin Recent Development Table 148. Corden Pharma Company Information Table 149. Corden Pharma Business Overview Table 150. Corden Pharma Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Corden Pharma Malignant Mesothelioma Drugs Product Portfolio Table 152. Corden Pharma Recent Development Table 153. Concordia International Company Information Table 154. Concordia International Business Overview Table 155. Concordia International Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 156. Concordia International Malignant Mesothelioma Drugs Product Portfolio Table 157. Concordia International Recent Development Table 158. Bristol-Myers Squibb Company Information Table 159. Bristol-Myers Squibb Business Overview Table 160. Bristol-Myers Squibb Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 161. Bristol-Myers Squibb Malignant Mesothelioma Drugs Product Portfolio Table 162. Bristol-Myers Squibb Recent Development Table 163. Boehringer Ingelheim GmbH Company Information Table 164. Boehringer Ingelheim GmbH Business Overview Table 165. Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 166. Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Product Portfolio Table 167. Boehringer Ingelheim GmbH Recent Development Table 168. Key Raw Materials Table 169. Raw Materials Key Suppliers Table 170. Malignant Mesothelioma Drugs Distributors List Table 171. Malignant Mesothelioma Drugs Customers List Table 172. Research Programs/Design for This Report Table 173. Authors List of This Report Table 174. Secondary Sources Table 175. Primary Sources List of Figures Figure 1. Malignant Mesothelioma Drugs Product Image Figure 2. Global Malignant Mesothelioma Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Malignant Mesothelioma Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Malignant Mesothelioma Drugs Sales (2021-2032) & (K Units) Figure 5. Global Malignant Mesothelioma Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Malignant Mesothelioma Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Vinorelbine Image Figure 9. Cisplatin Image Figure 10. Pemetrexed Image Figure 11. Carboplatin Image Figure 12. Gemcitabine Image Figure 13. Others Image Figure 14. Global Malignant Mesothelioma Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Malignant Mesothelioma Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Malignant Mesothelioma Drugs Sales Market Share by Type (2021-2032) Figure 17. Global Malignant Mesothelioma Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Malignant Mesothelioma Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2021-2032) Figure 20. Retail Pharmacies Image Figure 21. Hospital Pharmacies Image Figure 22. Oncology Centers Image Figure 23. Others Image Figure 24. Global Malignant Mesothelioma Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Malignant Mesothelioma Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Malignant Mesothelioma Drugs Sales Market Share by Application (2021-2032) Figure 27. Global Malignant Mesothelioma Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Malignant Mesothelioma Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Malignant Mesothelioma Drugs Revenue Market Share by Application (2021-2032) Figure 30. North America Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America Malignant Mesothelioma Drugs Sales Market Share by Country (2021-2032) Figure 32. U.S. Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Malignant Mesothelioma Drugs Sales Market Share by Country (2021-2032) Figure 37. Germany Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Malignant Mesothelioma Drugs Sales Market Share by Country (2021-2032) Figure 44. China Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Malignant Mesothelioma Drugs Sales Market Share by Country (2021-2032) Figure 52. Brazil Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile Malignant Mesothelioma Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global Malignant Mesothelioma Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Malignant Mesothelioma Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Figure 63. North America Malignant Mesothelioma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Figure 65. Europe Malignant Mesothelioma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Malignant Mesothelioma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Malignant Mesothelioma Drugs Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Malignant Mesothelioma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Malignant Mesothelioma Drugs Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Malignant Mesothelioma Drugs Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Vinorelbine
  • Cisplatin
  • Pemetrexed
  • Carboplatin
  • Gemcitabine
  • Others
Applications
  • Retail Pharmacies
  • Hospital Pharmacies
  • Oncology Centers
  • Others
Companies covered
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • Sanofi
  • Novartis
  • Merck
  • Mylan
  • Roche
  • Eli Lilly
  • Pfizer
  • Fresenius Kabi
  • AstraZeneca
  • Polaris Pharmaceuticals
  • Ono Pharmaceutical
  • Nichi-Iko Pharmaceutical
  • MolMed
  • Kyowa Hakko Kirin
  • Corden Pharma
  • Concordia International
  • Bristol-Myers Squibb
  • Boehringer Ingelheim GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Malignant Mesothelioma Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Malignant Mesothelioma Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Malignant Mesothelioma Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Malignant Mesothelioma Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Malignant Mesothelioma Drugs Market Dynamics
  1. 2.1 Malignant Mesothelioma Drugs Industry Trends
  2. 2.2 Malignant Mesothelioma Drugs Industry Drivers
  3. 2.3 Malignant Mesothelioma Drugs Industry Opportunities and Challenges
  4. 2.4 Malignant Mesothelioma Drugs Industry Restraints
3 Malignant Mesothelioma Drugs Market by Manufacturers
  1. 3.1 Global Malignant Mesothelioma Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Malignant Mesothelioma Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Malignant Mesothelioma Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Malignant Mesothelioma Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Malignant Mesothelioma Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Malignant Mesothelioma Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Malignant Mesothelioma Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Malignant Mesothelioma Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Malignant Mesothelioma Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Malignant Mesothelioma Drugs Tier 1, Tier 2, and Tier 3
4 Malignant Mesothelioma Drugs Market by Type
  1. 4.1 Malignant Mesothelioma Drugs Type Introduction
  2. 4.1.1 Vinorelbine
  3. 4.1.2 Cisplatin
  4. 4.1.3 Pemetrexed
  5. 4.1.4 Carboplatin
  6. 4.1.5 Gemcitabine
  7. 4.1.6 Others
  8. 4.2 Global Malignant Mesothelioma Drugs Sales by Type
  9. 4.2.1 Global Malignant Mesothelioma Drugs Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Malignant Mesothelioma Drugs Sales by Type (2021-2032)
  11. 4.2.3 Global Malignant Mesothelioma Drugs Sales Market Share by Type (2021-2032)
  12. 4.3 Global Malignant Mesothelioma Drugs Revenue by Type
  13. 4.3.1 Global Malignant Mesothelioma Drugs Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Malignant Mesothelioma Drugs Revenue by Type (2021-2032)
  15. 4.3.3 Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2021-2032)
5 Malignant Mesothelioma Drugs Market by Application
  1. 5.1 Malignant Mesothelioma Drugs Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Hospital Pharmacies
  4. 5.1.3 Oncology Centers
  5. 5.1.4 Others
  6. 5.2 Global Malignant Mesothelioma Drugs Sales by Application
  7. 5.2.1 Global Malignant Mesothelioma Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Malignant Mesothelioma Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global Malignant Mesothelioma Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Malignant Mesothelioma Drugs Revenue by Application
  11. 5.3.1 Global Malignant Mesothelioma Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Malignant Mesothelioma Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global Malignant Mesothelioma Drugs Revenue Market Share by Application (2021-2032)
6 Global Malignant Mesothelioma Drugs Sales by Region
  1. 6.1 Global Malignant Mesothelioma Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Malignant Mesothelioma Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Malignant Mesothelioma Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Malignant Mesothelioma Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Malignant Mesothelioma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Malignant Mesothelioma Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Malignant Mesothelioma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Malignant Mesothelioma Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Malignant Mesothelioma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Malignant Mesothelioma Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Malignant Mesothelioma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Malignant Mesothelioma Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Malignant Mesothelioma Drugs Revenue by Region
  1. 7.1 Global Malignant Mesothelioma Drugs Revenue by Region
  2. 7.1.1 Global Malignant Mesothelioma Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Malignant Mesothelioma Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Malignant Mesothelioma Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Malignant Mesothelioma Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Malignant Mesothelioma Drugs Revenue (2021-2032)
  8. 7.2.2 North America Malignant Mesothelioma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Malignant Mesothelioma Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Malignant Mesothelioma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Malignant Mesothelioma Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Malignant Mesothelioma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Malignant Mesothelioma Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Malignant Mesothelioma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceuticals
  2. 8.1.1 Teva Pharmaceuticals Company Information
  3. 8.1.2 Teva Pharmaceuticals Business Overview
  4. 8.1.3 Teva Pharmaceuticals Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio
  6. 8.1.5 Teva Pharmaceuticals Recent Developments
  7. 8.2 Sun Pharmaceuticals
  8. 8.2.1 Sun Pharmaceuticals Company Information
  9. 8.2.2 Sun Pharmaceuticals Business Overview
  10. 8.2.3 Sun Pharmaceuticals Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio
  12. 8.2.5 Sun Pharmaceuticals Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Malignant Mesothelioma Drugs Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Malignant Mesothelioma Drugs Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck Malignant Mesothelioma Drugs Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Mylan
  32. 8.6.1 Mylan Company Information
  33. 8.6.2 Mylan Business Overview
  34. 8.6.3 Mylan Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Mylan Malignant Mesothelioma Drugs Product Portfolio
  36. 8.6.5 Mylan Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Roche Malignant Mesothelioma Drugs Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Malignant Mesothelioma Drugs Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Malignant Mesothelioma Drugs Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Fresenius Kabi
  56. 8.10.1 Fresenius Kabi Company Information
  57. 8.10.2 Fresenius Kabi Business Overview
  58. 8.10.3 Fresenius Kabi Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Fresenius Kabi Malignant Mesothelioma Drugs Product Portfolio
  60. 8.10.5 Fresenius Kabi Recent Developments
  61. 8.11 AstraZeneca
  62. 8.11.1 AstraZeneca Company Information
  63. 8.11.2 AstraZeneca Business Overview
  64. 8.11.3 AstraZeneca Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 AstraZeneca Malignant Mesothelioma Drugs Product Portfolio
  66. 8.11.5 AstraZeneca Recent Developments
  67. 8.12 Polaris Pharmaceuticals
  68. 8.12.1 Polaris Pharmaceuticals Company Information
  69. 8.12.2 Polaris Pharmaceuticals Business Overview
  70. 8.12.3 Polaris Pharmaceuticals Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Polaris Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio
  72. 8.12.5 Polaris Pharmaceuticals Recent Developments
  73. 8.13 Ono Pharmaceutical
  74. 8.13.1 Ono Pharmaceutical Company Information
  75. 8.13.2 Ono Pharmaceutical Business Overview
  76. 8.13.3 Ono Pharmaceutical Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Ono Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio
  78. 8.13.5 Ono Pharmaceutical Recent Developments
  79. 8.14 Nichi-Iko Pharmaceutical
  80. 8.14.1 Nichi-Iko Pharmaceutical Company Information
  81. 8.14.2 Nichi-Iko Pharmaceutical Business Overview
  82. 8.14.3 Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio
  84. 8.14.5 Nichi-Iko Pharmaceutical Recent Developments
  85. 8.15 MolMed
  86. 8.15.1 MolMed Company Information
  87. 8.15.2 MolMed Business Overview
  88. 8.15.3 MolMed Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 MolMed Malignant Mesothelioma Drugs Product Portfolio
  90. 8.15.5 MolMed Recent Developments
  91. 8.16 Kyowa Hakko Kirin
  92. 8.16.1 Kyowa Hakko Kirin Company Information
  93. 8.16.2 Kyowa Hakko Kirin Business Overview
  94. 8.16.3 Kyowa Hakko Kirin Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Kyowa Hakko Kirin Malignant Mesothelioma Drugs Product Portfolio
  96. 8.16.5 Kyowa Hakko Kirin Recent Developments
  97. 8.17 Corden Pharma
  98. 8.17.1 Corden Pharma Company Information
  99. 8.17.2 Corden Pharma Business Overview
  100. 8.17.3 Corden Pharma Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Corden Pharma Malignant Mesothelioma Drugs Product Portfolio
  102. 8.17.5 Corden Pharma Recent Developments
  103. 8.18 Concordia International
  104. 8.18.1 Concordia International Company Information
  105. 8.18.2 Concordia International Business Overview
  106. 8.18.3 Concordia International Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Concordia International Malignant Mesothelioma Drugs Product Portfolio
  108. 8.18.5 Concordia International Recent Developments
  109. 8.19 Bristol-Myers Squibb
  110. 8.19.1 Bristol-Myers Squibb Company Information
  111. 8.19.2 Bristol-Myers Squibb Business Overview
  112. 8.19.3 Bristol-Myers Squibb Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Bristol-Myers Squibb Malignant Mesothelioma Drugs Product Portfolio
  114. 8.19.5 Bristol-Myers Squibb Recent Developments
  115. 8.20 Boehringer Ingelheim GmbH
  116. 8.20.1 Boehringer Ingelheim GmbH Company Information
  117. 8.20.2 Boehringer Ingelheim GmbH Business Overview
  118. 8.20.3 Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Product Portfolio
  120. 8.20.5 Boehringer Ingelheim GmbH Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Malignant Mesothelioma Drugs Value Chain Analysis
  2. 9.1.1 Malignant Mesothelioma Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Malignant Mesothelioma Drugs Production Mode & Process
  6. 9.2 Malignant Mesothelioma Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Malignant Mesothelioma Drugs Distributors
  9. 9.2.3 Malignant Mesothelioma Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst